SERDSchool of Environment, Resources and Development (Thailand)
SERDSocio-Economic Resource Development (investment model)
SERDSoft-Error Rate Discrimination (computer algorithm)
SERDSupport Equipment Requirements Document
SERDselective estrogen receptor down-regulator
SERDSupport Equipment Requirements Data
SERDSystem Engineering Requirements Document
SERDSupport Equipment Recommendations Data
SERDStored Energy Rotary Drive
Copyright 1988-2018, All rights reserved.
References in periodicals archive ?
With this acquisition, Genentech obtains rights to Seragon's entire portfolio of investigational next-generation oral selective estrogen receptor degraders (SERDs) for the potential treatment of hormone receptor-positive breast cancer.
"We believe these investigational oral SERDs could one day redefine the standard of care for hormone receptor-positive breast cancer."
Three main components can be distinguished in figure 1: SERDS is the DBMS server, SNC implements database specific protocols on top of the general LAN software on Lilith, called CIPON, and SAM is the main program coordinating all the activities on the server.
SERDS (server relational data system) is a multi user DBMS which was developed starting from RDS.
As such, its main task consists of scheduling the requests received from SNC for execution by SERDS and of passing back the corresponding answers.
Classes of drugs examined include SERMs and SERDs, aromatase inhibitors, microtubule binding agents, HER family inhibitors, angiogenesis inhibitors, miotic inhibitors, vaccines and immunomodulators, cyclooxygenase-2 inhibitors, and inhibitors of heat-shock proteins 90 and 27.
Promising data suggest that a new group of drugs known as selective estrogen receptor down-regulators (SERDs) may be even more potent and better tolerated.
SERCAs have a unique biological and activity profile compared to Selective Estrogen Receptor Modulators (SERMs) and Selective Estrogen Receptor Degraders (SERDs).
The target, based in San Diego, California, specialises in the development of selective estrogen receptor degraders (SERDs) for hormone receptor-driven cancers.
Through the takeover, the buyer will gain rights to Seragon's portfolio of investigational next-generation oral SERDs for the potential treatment of hormone receptor-positive breast cancer.